{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:41:25Z","timestamp":1790764885051,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["PI15-00255"],"award-info":[{"award-number":["PI15-00255"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["PI08-1449"],"award-info":[{"award-number":["PI08-1449"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"crossref","award":["B2017\/BMD3673"],"award-info":[{"award-number":["B2017\/BMD3673"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Asociacio\u0301n Espan\u0303ola de Familiares y Afectados de Lipodistrofias"},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["ED341b 2017\/19"],"award-info":[{"award-number":["ED341b 2017\/19"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>C3 hypocomplementemia and the presence of C3 nephritic factor (C3NeF), an autoantibody causing complement system over-activation, are common features among most patients affected by Barraquer-Simons syndrome (BSS), an acquired form of partial lipodystrophy. Moreover, BSS is frequently associated with autoimmune diseases. However, the relationship between complement system dysregulation and BSS remains to be fully elucidated. The aim of this study was to provide a comprehensive immunological analysis of the complement system status, autoantibody signatures and HLA profile in BSS. Thirteen subjects with BSS were recruited for the study. The circulating levels of complement components, C3, C4, Factor B (FB) and Properdin (P), as well as an extended autoantibody profile including autoantibodies targeting complement components and regulators were assessed in serum. Additionally, HLA genotyping was carried out using DNA extracted from peripheral blood mononuclear cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>C3, C4 and FB levels were significantly reduced in patients with BSS as compared with healthy subjects. C3NeF was the most frequently found autoantibody (69.2% of cases), followed by anti-C3 (38.5%), and anti-P and anti-FB (30.8% each). Clinical data showed high prevalence of autoimmune diseases (38.5%), the majority of patients (61.5%) being positive for at least one of the autoantibodies tested. The HLA allele DRB1*11 was present in 54% of BSS patients, and the majority of them (31%) were positive for *11:03 (vs 1.3% allelic frequency in the general population).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results confirmed the association between BSS, autoimmunity and C3 hypocomplementemia. Moreover, the finding of autoantibodies targeting complement system proteins points to complement dysregulation as a central pathological event in the development of BSS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-019-1292-1","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T17:03:01Z","timestamp":1578675781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunological features of patients affected by Barraquer-Simons syndrome"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-5647","authenticated-orcid":false,"given":"Fernando","family":"Corvillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ceccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nozal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Pelosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"L\u00f3pez-Lera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Moraru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vilches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fornaciari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Gabbriellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"L\u00f3pez-Trascasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","volume":"42","author":"D Ara\u00fajo-Vilar","year":"2019","unstructured":"Ara\u00fajo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Investig. 2019;42:61\u201373.","journal-title":"J Endocrinol Investig"},{"key":"1292_CR2","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220\u201334.","journal-title":"N Engl J Med"},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","volume":"45","author":"I Hussain","year":"2016","unstructured":"Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin N Am. 2016;45:783\u201397.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"1292_CR4","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and Management of Lipodystrophy Syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101:4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83:18\u201334.","journal-title":"Medicine (Baltimore)"},{"key":"1292_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/07435800.2018.1513029","volume":"44","author":"B Ozgen Saydam","year":"2019","unstructured":"Ozgen Saydam B, Sonmez M, Simsir IY, Erturk MS, Kulaksizoglu M, Arkan T, et al. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities. Endocr Res. 2019;44:46\u201354.","journal-title":"Endocr Res"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jaad.2006.05.005","volume":"55","author":"E Pope","year":"2006","unstructured":"Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006;55:947\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM197602262940902","volume":"294","author":"JG Sissons","year":"1976","unstructured":"Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, et al. The complement abnormalities of lipodystrophy. N Engl J Med. 1976;294:461\u20135.","journal-title":"N Engl J Med"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcdb.2017.12.017","volume":"85","author":"A L\u00f3pez-Lera","year":"2019","unstructured":"L\u00f3pez-Lera A, Corvillo F, Nozal P, Regueiro JR, S\u00e1nchez-Corral P, L\u00f3pez-Trascasa M. Complement as a diagnostic tool in immunopathology. Semin Cell Dev Biol. 2019;85:86\u201397.","journal-title":"Semin Cell Dev Biol"},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaci.2017.02.018","volume":"140","author":"D Levy Erez","year":"2017","unstructured":"Levy Erez D, Meyers KE, Sullivan KE. C3 nephritic factors: a changing landscape. J Allergy Clin Immunol. 2017;140:57\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ndt\/gfy220","volume":"34","author":"S Sethi","year":"2019","unstructured":"Sethi S, Fervenza FC. Standardized classification and reporting of glomerulonephritis. Nephrol Dial Transplant. 2019;34:193\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nep.13461","volume":"23","author":"Y Tan","year":"2018","unstructured":"Tan Y, Zhao M-H. Complement in glomerular diseases: complement in glomerular diseases. Nephrology. 2018;23:11\u20135.","journal-title":"Nephrology"},{"key":"1292_CR13","doi-asserted-by":"crossref","unstructured":"Smith RJH, Appel GB, Blom AM, Cook HT, D\u2019Agati VD, Fakhouri F, et al. C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15:129\u201343.","DOI":"10.1038\/s41581-018-0107-2"},{"key":"1292_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.2734615","volume":"244","author":"BS Rosen","year":"1989","unstructured":"Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis JE, Damm D, et al. Adipsin and complement factor D activity: an immune-related defect in obesity. Science. 1989;244:1483\u20137.","journal-title":"Science."},{"key":"1292_CR15","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1016\/S0021-9258(19)50409-4","volume":"267","author":"RT White","year":"1992","unstructured":"White RT, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. 1992;267:9210\u20133.","journal-title":"J Biol Chem"},{"key":"1292_CR16","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.4049\/jimmunol.1701668","volume":"200","author":"X Wu","year":"2018","unstructured":"Wu X, Hutson I, Akk AM, Mascharak S, Pham CTN, Hourcade DE, et al. Contribution of adipose-derived factor D\/Adipsin to complement alternative pathway activation: lessons from Lipodystrophy. J Immunol. 2018;200:2786\u201397.","journal-title":"J Immunol"},{"key":"1292_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.molimm.2008.09.013","volume":"46","author":"M Pattrick","year":"2009","unstructured":"Pattrick M, Luckett J, Yue L, Stover C. Dual role of complement in adipose tissue. Mol Immunol. 2009;46:755\u201360.","journal-title":"Mol Immunol"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2337\/db09-0700","volume":"59","author":"JM Moreno-Navarrete","year":"2010","unstructured":"Moreno-Navarrete JM, Mart\u00ednez-Barricarte R, Catal\u00e1n V, Sabater M, G\u00f3mez-Ambrosi J, Ortega FJ, et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes. 2010;59:200\u20139.","journal-title":"Diabetes."},{"key":"1292_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molimm.2012.02.110","volume":"51","author":"D Gauvreau","year":"2012","unstructured":"Gauvreau D, Roy C, Tom F-Q, Lu H, Miegueu P, Richard D, et al. A new effector of lipid metabolism: complement factor properdin. Mol Immunol. 2012;51:73\u201381.","journal-title":"Mol Immunol"},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bbrc.2017.11.069","volume":"495","author":"H Matsunaga","year":"2018","unstructured":"Matsunaga H, Iwashita M, Shinjo T, Yamashita A, Tsuruta M, Nagasaka S, et al. Adipose tissue complement factor B promotes adipocyte maturation. Biochem Biophys Res Commun. 2018;495:740\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1292_CR21","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1084\/jem.177.6.1827","volume":"177","author":"PW Mathieson","year":"1993","unstructured":"Mathieson PW, W\u00fcrzner R, Oliveria DB, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med. 1993;177:1827\u201331.","journal-title":"J Exp Med"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.humimm.2019.02.005","volume":"80","author":"G Montero-Mart\u00edn","year":"2019","unstructured":"Montero-Mart\u00edn G, Mallempati KC, Gangavarapu S, S\u00e1nchez-Gordo F, Herrero-Mata MJ, Balas A, et al. High-resolution characterization of allelic and haplotypic HLA frequency distribution in a Spanish population using high-throughput next-generation sequencing. Hum Immunol. 2019;80:429\u201336.","journal-title":"Hum Immunol"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12754","volume":"184","author":"F Corvillo","year":"2016","unstructured":"Corvillo F, Bravo Garc\u00eda-Morato M, Nozal P, Garrido S, Tortajada A, Rodr\u00edguez de C\u00f3rdoba S, et al. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol. 2016;184:118\u201325.","journal-title":"Clin Exp Immunol"},{"key":"1292_CR24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","volume":"82","author":"D Paix\u00e3o-Cavalcante","year":"2012","unstructured":"Paix\u00e3o-Cavalcante D, L\u00f3pez-Trascasa M, Skattum L, Giclas PC, Goodship TH, de C\u00f3rdoba SR, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 2012;82:1084\u201392.","journal-title":"Kidney Int"},{"key":"1292_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2249.1994.tb06530.x","volume":"95","author":"H Ohi","year":"1994","unstructured":"Ohi H, Yasugi T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol. 1994;95:316\u201321.","journal-title":"Clin Exp Immunol"},{"key":"1292_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/jc.2008-1703","volume":"94","author":"DB Savage","year":"2009","unstructured":"Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94:10\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4274\/jcrpe.v2i1.39","volume":"2","author":"E Eren","year":"2010","unstructured":"Eren E, \u00d6zkan TB, \u00c7ak\u0131r EDP, Sa\u011flam H, Tar\u0131m \u00d6. Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level. J Clin Res Pediatr Endocrinol. 2010;2:39\u201342.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"1292_CR28","doi-asserted-by":"crossref","unstructured":"Gaya da Costa M, Poppelaars F, van Kooten C, Mollnes TE, Tedesco F, W\u00fcrzner R, et al. Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. Front Immunol. 2018; [cited 2019 Nov 15];9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6255829\/.","DOI":"10.3389\/fimmu.2018.02664"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0022-3476(75)80904-8","volume":"87","author":"ME Norman","year":"1975","unstructured":"Norman ME, Gall EP, Taylor A, Laster L, Nilsson UR. Serum complement profiles in infants and children. J Pediatr. 1975;87:912\u20136.","journal-title":"J Pediatr"},{"key":"1292_CR30","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","volume":"47","author":"S Strobel","year":"2010","unstructured":"Strobel S, Zimmering M, Papp K, Prechl J, J\u00f3zsi M. Anti-factor B autoantibody in dense deposit disease. Mol Immunol. 2010;47:1476\u201383.","journal-title":"Mol Immunol"},{"key":"1292_CR31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMc1107484","volume":"365","author":"Q Chen","year":"2011","unstructured":"Chen Q, M\u00fcller D, Rudolph B, Hartmann A, Kuwertz-Br\u00f6king E, Wu K, et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med. 2011;365:2340\u20132.","journal-title":"N Engl J Med"},{"key":"1292_CR32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","volume":"28","author":"MC Marinozzi","year":"2017","unstructured":"Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, et al. Anti-factor B and anti-C3b autoantibodies in C3 Glomerulopathy and Ig-associated Membranoproliferative GN. J Am Soc Nephrol. 2017;28:1603\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"1292_CR33","doi-asserted-by":"publisher","first-page":"25343","DOI":"10.1074\/jbc.M115.647008","volume":"290","author":"VV Vasilev","year":"2015","unstructured":"Vasilev VV, Noe R, Dragon-Durey M-A, Chauvet S, Lazarov VJ, Deliyska BP, et al. Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis. J Biol Chem. 2015;290:25343\u201355.","journal-title":"J Biol Chem"},{"key":"1292_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fimmu.2019.00064","volume":"10","author":"VV Vasilev","year":"2019","unstructured":"Vasilev VV, Radanova M, Lazarov VJ, Dragon-Durey M-A, Fremeaux-Bacchi V, Roumenina LT. Autoantibodies against C3b-functional consequences and disease relevance. Front Immunol. 2019;10:64.","journal-title":"Front Immunol"},{"key":"1292_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000381844","volume":"7","author":"Y Muto","year":"2015","unstructured":"Muto Y, Fujimura T, Kakizaki A, Tsuchiyama K, Kusakari Y, Aiba S. Adult-onset acquired partial Lipodystrophy accompanied by rheumatoid arthritis. Case Rep Dermatol. 2015;7:70\u20134.","journal-title":"Case Rep Dermatol"},{"key":"1292_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12016-007-8013-6","volume":"34","author":"R Maya","year":"2008","unstructured":"Maya R, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol. 2008;34:85\u2013102.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1292_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.autrev.2008.06.008","volume":"7","author":"M Ram","year":"2008","unstructured":"Ram M, Anaya J-M, Barzilai O, Izhaky D, Porat Katz B-S, Blank M, et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev. 2008;7:621\u20135.","journal-title":"Autoimmun Rev"},{"key":"1292_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0029-1211955","volume":"106","author":"A H\u00fcbler","year":"1998","unstructured":"H\u00fcbler A, Abendroth K, Keiner T, St\u00f6cker W, Kauf E, Hein G, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes. 1998;106:79\u201384.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1292_CR39","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(74)90021-X","volume":"1","author":"HO McDevitt","year":"1974","unstructured":"McDevitt HO, Bodmer WF. HL-A, immune-response genes, and disease. Lancet. 1974;1:1269\u201375.","journal-title":"Lancet."},{"key":"1292_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1399-0039.2009.01436.x","volume":"75","author":"A Balas","year":"2010","unstructured":"Balas A, Garc\u00eda-S\u00e1nchez F, Vicario JL. A new DQA1 allele (DQA1*0510) in a Spanish celiac disease patient. Tissue Antigens. 2010;75:287\u20138.","journal-title":"Tissue Antigens"},{"key":"1292_CR41","doi-asserted-by":"crossref","unstructured":"Farina F, Picascia S, Pisapia L, Barba P, Vitale S, Franzese A, et al. HLA-DQA1 and HLA-DQB1 alleles, conferring susceptibility to celiac disease and type 1 diabetes, are more expressed than non-predisposing alleles and are coordinately regulated. Cells. 2019;8:751.","DOI":"10.3390\/cells8070751"},{"key":"1292_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13075-018-1724-7","volume":"20","author":"M Ar\u00e9valo","year":"2018","unstructured":"REGISPONSER group, Ar\u00e9valo M, Gratac\u00f3s Masmitj\u00e0 J, Moreno M, Calvet J, Orellana C, et al. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Res Ther. 2018;20:221.","journal-title":"Arthritis Res Ther"},{"key":"1292_CR43","doi-asserted-by":"crossref","unstructured":"Kanga U, Tandon N, Marwaha RK, Khanna R, Bhattacharya B, Singh S, et al. Immunogenetic association and thyroid autoantibodies in juvenile autoimmune thyroiditis in North India. Clin Endocrinol. 2006; [cited 2019 Aug 8]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1365-2265.2006.02511.x.","DOI":"10.1111\/j.1365-2265.2006.02511.x"},{"key":"1292_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/bjh.12956","volume":"166","author":"E Arons","year":"2014","unstructured":"Arons E, Adams S, Venzon DJ, Pastan I, Kreitman RJ. Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. Br J Haematol. 2014;166:729\u201338.","journal-title":"Br J Haematol"},{"key":"1292_CR45","first-page":"1481","volume":"32","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P. HLA markers for susceptibility and expression in scleroderma. J Rheumatol. 2005;32:1481\u20137.","journal-title":"J Rheumatol"},{"key":"1292_CR46","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00296-012-2661-4","volume":"33","author":"X He","year":"2013","unstructured":"He X, Yu C, Zhao P, Ding Y, Liang X, Zhao Y, et al. The genetics of Henoch-Sch\u00f6nlein purpura: a systematic review and meta-analysis. Rheumatol Int. 2013;33:1387\u201395.","journal-title":"Rheumatol Int"},{"key":"1292_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/09537100400028685","volume":"16","author":"D Veneri","year":"2005","unstructured":"Veneri D, De Matteis G, Solero P, Federici F, Zanuso C, Guizzardi E, et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with helicobacter pylori infection and response to eradication treatment. Platelets. 2005;16:307\u201311.","journal-title":"Platelets."},{"key":"1292_CR48","doi-asserted-by":"publisher","first-page":"15970","DOI":"10.1073\/pnas.1520779112","volume":"112","author":"MJ Ombrello","year":"2015","unstructured":"Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas J-P, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112:15970\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1292_CR49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1365-2141.2002.03926.x","volume":"119","author":"I Theodorou","year":"2002","unstructured":"Theodorou I, Abel L, Mauro F, Duprey B, Magnac C, Payelle-Brogard B, et al. High occurence of DRB1 11 in chronic lymphocytic leukaemia families. Br J Haematol. 2002;119:713\u20135.","journal-title":"Br J Haematol"},{"issue":"Suppl 10","key":"1292_CR50","first-page":"S7","volume":"12","author":"JP Haas","year":"1994","unstructured":"Haas JP, Truckenbrodt H, Paul C, Hoza J, Scholz S, Albert ED. Subtypes of HLA-DRB1*03, *08, *11, *12, *13 and *14 in early onset pauciarticular juvenile chronic arthritis (EOPA) with and without iridocyclitis. Clin Exp Rheumatol. 1994;12(Suppl 10):S7\u201314.","journal-title":"Clin Exp Rheumatol"},{"key":"1292_CR51","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/art.27424","volume":"62","author":"JA Hollenbach","year":"2010","unstructured":"Hollenbach JA, Thompson SD, Bugawan TL, Ryan M, Sudman M, Marion M, et al. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum. 2010;62:1781\u201391.","journal-title":"Arthritis Rheum"},{"key":"1292_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12882-015-0032-6","volume":"16","author":"P Nozal","year":"2015","unstructured":"Nozal P, Garrido S, Mart\u00ednez-Ara J, Picazo ML, Y\u00e9benes L, \u00c1lvarez-Doforno R, et al. Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation. BMC Nephrol. 2015;16:40.","journal-title":"BMC Nephrol"},{"key":"1292_CR53","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","volume":"114","author":"C Abarrategui-Garrido","year":"2009","unstructured":"Abarrategui-Garrido C, Mart\u00ednez-Barricarte R, L\u00f3pez-Trascasa M, de C\u00f3rdoba SR, S\u00e1nchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood. 2009;114:4261\u201371.","journal-title":"Blood"},{"key":"1292_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1399-0039.2009.01400.x","volume":"75","author":"A Balas","year":"2010","unstructured":"Balas A, Garc\u00eda-S\u00e1nchez F, Vicario LJ. The new HLA-Cw*0442 allele possibly generated by a recombination event involving Cw*04010101 and Cw*1801. Tissue Antigens. 2010;75:82\u20133.","journal-title":"Tissue Antigens"},{"key":"1292_CR55","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1399-0039.2009.01430.x","volume":"75","author":"A Balas","year":"2010","unstructured":"Balas A, Garc\u00eda-S\u00e1nchez F, Vicario JL. HLA-B*4907 and B*490101 differs by residue 163 placed in a dominant serologic epitope. Tissue Antigens. 2010;75:286\u20137.","journal-title":"Tissue Antigens"},{"key":"1292_CR56","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1399-0039.2009.01431.x","volume":"75","author":"A Balas","year":"2010","unstructured":"Balas A, Garc\u00eda-S\u00e1nchez F, Vicario JL. Sequencing of a new HLA-DRB1*16 allele (DRB1*1615) with valine at residue 86. Tissue Antigens. 2010;75:288\u20139.","journal-title":"Tissue Antigens"},{"key":"1292_CR57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-1-4939-2690-9_19","volume":"1310","author":"M Testi","year":"2015","unstructured":"Testi M, Andreani M. Luminex-based methods in high-resolution HLA typing. Methods Mol Biol. 2015;1310:231\u201345.","journal-title":"Methods Mol Biol"}],"updated-by":[{"DOI":"10.1186\/s13023-020-1350-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1292-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T01:24:56Z","timestamp":1610155496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1292-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13023-020-1350-8","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following the publication of the original article [1], the authors have requested to amend the Abstract and Discussion section as follows.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Research Ethics Committee of La Paz University Hospital (project code PI-2276) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All participants provided written informed consent for participation in the study and for the publication of their clinical and biochemical information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}